Joseph Shapiro, MD
Allergy & Immunology · Studio City, CANPI 1528070737
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,095 of the $1,665 with a category attached, or 65.8%. Sanofi accounts for 71.1% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2022 at $1,120 and has fallen 91.5% since, to $96 in 2024. That places this record below the midpoint for allergy & immunology clinicians in CA, where the typical reported total is $2,148.
Across 13 payments — averaging $128.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$1K
- AstraZeneca$135
- Amgen$124
- Regeneron Healthcare Solutions, Inc.$96
- Novartis$58
- Genentech, Inc.$48
- plus $19 from 1 others
Across 7 payments — averaging $6585.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$46K
What the payments were for
- Consulting fees$1,09566%
- Food & beverage$51131%
- Education$604%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 5 | $1,185 |
| AstraZeneca | 2 | $135 |
| Amgen | 1 | $124 |
| Regeneron Healthcare Solutions, Inc. | 1 | $96 |
| Novartis | 2 | $58 |
| Genentech, Inc. | 1 | $48 |
| GSK | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$1,095
How this compares
$1,665 in reported general payments places this provider in the 45th percentile of 426 allergy & immunology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 46 | $278,747 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 153 | $126,201 |
| Dupixent SyringeDupilumab | 12 | $117,985 |
| XolairOmalizumab | 11 | $111,364 |
| Dupixent PenDupilumab | 11 | $93,533 |
| Spiriva RespimatTiotropium Bromide | 56 | $46,757 |
| Breo ElliptaFluticasone/Vilanterol | 63 | $32,816 |
| XembifyImmune Globulin,gamma(Igg)klhw | 17 | $20,289 |
| RyaltrisOlopatadine Hcl/Mometasone | 43 | $14,498 |
| Qvar RedihalerBeclomethasone Dipropionate | 39 | $14,014 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 115 | $11,473 |
| DuleraMometasone/Formoterol | 17 | $8,363 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $6,061 |
| Fluticasone Propionate HfaFluticasone Propionate | 12 | $5,417 |
| Arnuity ElliptaFluticasone Furoate | 17 | $4,245 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $19 | $163,262233 claims |
| Genentech, Inc.Xolair | $48 | $111,36411 claims |
| AstraZenecaSymbicort | $135 | $6,06121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 426 allergy & immunology providers in California.
Other allergy & immunology in Studio City
- Raffi TachdjianSanta Monica$3.7M
- Bob GengSan Diego$3.3M
- Vinay MehtaLaguna Niguel$1.3M
- Andrew WhiteSan Diego$752K
- Marc RiedlSan Diego$725K
- Katharine WoessnerSan Diego$581K
- Brian Modenala Jolla$453K
- Heena Shah PatelUpland$428K
- Jacob OffenbergerGranada Hills$419K
- Myron LiebhaberSanta Barbara$354K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.